CommentaryCommentary: Does Asymptomatic Bacteriuria Reduce the Risk of Recurrence of Non–muscle-invasive Bladder Tumors?
Section snippets
Comment
In these 2 cohorts of patients at high risk of recurrent NMIBC, those with chronic ABU had fewer recurrences, fewer numbers of recurrent tumors, and longer tumor-free survival times than similarly staged uninfected patients, leading us to hypothesize that bacteriuria may have a biologic effect in reducing the risk of recurrence. A mechanism to explain how this might occur is unknown, but one possibility is that chronic bacteriuria may act similarly to BCG in inducing a local immune response
References (10)
The risk of urinary tract infection after flexible cystoscopy in patients with bladder tumor who did not receive prophylactic antibiotics
J Urol
(2015)- et al.
From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa
Mucosal Immunol
(2013) - et al.
BCG without maintenance therapy for high-risk non-muscle-invasive bladder cancer
Eur Urol
(2011) - et al.
Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006
Cancer
(2014) - et al.
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables
Eur Urol
(2006)
There are more references available in the full text version of this article.
Cited by (6)
A short course of antimicrobial therapy for asymptomatic bacteriuria is safe and effective before urologic procedures
2021, Journal of Infection in Developing CountriesSpectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine
2017, Journal of Cancer Research and Clinical Oncology
© 2016 Elsevier Inc. All rights reserved.